Floatz logo

Methylphenidate

Chronic Pain Syndrome

University of RochesterSmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

100 Active assets in the Chronic Pain Syndrome cohort.

Asset / SponsorPhaseRating
(±)-TRAMADOL
EMS
Phase 4BBB
METHADONE
Cari Health Inc.
Phase 4BBB
LIDOCAINE
National and Kapodistrian University of Athens
Phase 4BBB
NEPENTHE
Bursa City Hospital
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BBB

View all 50 →

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderDormant
BBB
Indicative ·
76 / 100
View asset →
ApathyDormant
BBB
Indicative ·
72 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →